cd20xcd3
(2)
Prolium Bioscience
Prolium Bioscience is a New York-based, clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager designed to deplete disease-driving B cells as an off-the-shelf therapy for severe autoimmune diseases, starting with systemic sclerosis and lupus. Founded in 2025 and backed by RTW Investments, the company in-licensed global non-oncology and ex-Asia oncology rights to the antibody from China's InnoCare Pharma and KeyMed Biosciences, and launched publicly in March 2026 with a $50 million Series A alongside first-patient dosing.
Scott Requadt
Scott Requadt is the founding CEO of Prolium Bioscience, a New York-based biotech that emerged from stealth in March 2026 with a $50M Series A from RTW and a Phase 1/2-ready CD20xCD3 bispecific T-cell engager, PRO-203, in-licensed from KeyMed Biosciences and InnoCare Pharma for severe autoimmune disease. A lawyer-turned-investor-turned-operator, Requadt spent a decade at Clarus Ventures (later Blackstone Life Sciences) as Managing Director, ran Talaris Therapeutics as CEO from 2018 through its 2023 wind-down, and now sits on the board of ESSA Pharmaceuticals. He trained at McGill, Toronto Law, and Harvard Business School (Baker Scholar), started his career as an M&A attorney at Davis Polk, and has spent the intervening twenty years turning that unusual pedigree into biotech deals.